4D Molecular Therapeutics, Inc. (FDMT) News
Follow 4D Molecular Therapeutics, Inc. (FDMT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
FDMT Q3'26 Earnings Preview: Revenue Estimate
4D Molecular Therapeutics is scheduled to report Q3'26 results on November 11. The report time is not specified.
EQUITY | Nov 04, 2026, 12:01 PM UTC
L
4D Molecular Therapeutics Price Target Raised to $33.00/Share From $29.00 by B of A Securities
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 12:33 PM UTC
L
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
Shares of Ocular Therapeutix (OCUL) dropped more than 22% on Monday as investors reacted to upbeat late-stage results from two competitors targeting the same crowded market for longer-lasting wet age-related macular dege
EQUITY | Sep 28, 2026, 05:16 PM UTC
L
4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT; SPECTRA shows +10.8 BCVA gain, 61% treatment-burden reduction
4D Molecular Therapeutics announced first patient enrollments in the global Phase 3 4SIGHT trial of 4D-150 for DME and reported 2-year SPECTRA data showing clinical activity and reduced treatment burden.Key Highlights:Or
REGULATION | Sep 28, 2026, 12:16 PM UTC
L
4D Molecular Therapeutics (FDMT) Starts Phase 3 4SIGHT Trial in DME
4D Molecular Therapeutics initiated 4SIGHT, a Phase 3 trial of 4D-150 in diabetic macular edema, with first patients enrolled and FDA RMAT designation noted.Material DetailsContext by AI AnalystThis is a late-stage devel
REGULATION | Sep 28, 2026, 12:01 PM UTC
L
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po
NEWS | Sep 28, 2026, 12:01 PM UTC
L
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial momentum in retinal diseases
The session highlighted the progress of a next-gen gene therapy platform, with 4D-150 advancing in wet AMD and DME. Strong clinical data, rapid trial enrollment, and a robust commercial partnership with Otsuka support gl
NEWS | Sep 14, 2026, 11:02 PM UTC
L
FDMT: Gene therapy platform advances with strong phase III momentum, robust safety, and commercial readiness
Revised summary: The session highlighted advances in next-gen gene therapy, with 4D-150 showing strong safety and efficacy in wet AMD and DME. Rapid enrollment and positive feedback support robust phase III trials. Comme
NEWS | Sep 14, 2026, 10:38 PM UTC
L
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po
NEWS | Sep 11, 2026, 08:11 PM UTC
L
FDMT - 4DMT Announces New Employment Inducement Grants
FDMT - 4DMT Announces New Employment Inducement Grants
NEWS | Sep 11, 2026, 08:05 PM UTC
L
4D-150 Phase III wet AMD trials fully enrolled; data due next year
4D-150 Phase III trials in wet AMD are fully enrolled. Major data readouts are expected next year for the therapy aimed at reducing treatment burden and preserving vision.
EQUITY | Sep 10, 2026, 03:33 PM UTC
L
FDMT - 4DMT to Participate in Upcoming Investor Conferences
FDMT - 4DMT to Participate in Upcoming Investor Conferences
EQUITY | Aug 25, 2026, 12:01 PM UTC
L
FDMT/4DMT announces new employment inducement grants
FDMT, also known as 4DMT, announces new employment inducement grants, with no further details provided in the feed.
EQUITY | Aug 14, 2026, 08:05 PM UTC
L
4DMT (FDMT) reports Q2 2026 financial results and operational highlights
FDMT—4DMT reports its second quarter 2026 financial results along with operational highlights and expected upcoming milestones.
EARNINGS | Aug 13, 2026, 08:05 PM UTC
H
FDMT Initiated Buy at B.Riley
B.Riley initiates FDMT buy
EQUITY | Jul 31, 2026, 11:55 AM UTC
H
Cantor Initiates DUOT Overweight
Banks initiate coverage on several stocks
EQUITY | Jul 31, 2026, 11:38 AM UTC
H
FDMT Rated Buy
FDMT rated new buy
EQUITY | Jul 31, 2026, 11:23 AM UTC
L
FDMT - per Saturday PR: 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In
FDMT - per Saturday PR: 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup
EQUITY | Jul 20, 2026, 01:15 PM UTC